[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642651":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":30,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Northside Hospital, Inc.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Axatilimab + Commercial CAR T cell therapy","EXPERIMENTAL",null,[13],"Drug: Axatilimab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Axatilimab","Dose Level -1: 0.1mg\u002Fkg Dose Level +1: 0.3mg\u002Fkg Dose Level +2: 1mg\u002Fkg Dose Level +3: 3mg\u002Fkg",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Joseph Maakaron, MD","CONTACT","404-255-1930","jmaakaron@bmtga.com",{"name":27,"role":23,"phone":28,"phoneExt":11,"email":29},"Caitlin Guzowski, MBA, MHA, CCRC","404-851-8523","caitlin.guzowski@northside.com",[31],{"facility":32,"status":11,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Northside Hospital","Atlanta","Georgia","30342","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-84.38798,33.749,{"lat":42,"lon":41},[45],{"name":27,"role":23,"phone":28,"phoneExt":11,"email":29},{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100642651","phase-1-axatilimab--car-t-for-high-risk-lymphoma-100642651",false,"NCT07638982","Axatilimab + CAR-T for High-Risk Lymphoma","An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed large B-cell lymphoma\n* Presence of one or more high-risk features\n* Eligible to receive CAR-T according to the FDA label\n* Measurable disease by CT or PET\n* Adequate organ function unless related to lymphoma involvement:\n* Pulse oximetry ≥ 92% on room air\n* Ejection Fraction ≥ 40%\n* ALT\u002FAST \\\u003C 5x ULN\n* Bilirubin \\\u003C 3 x ULN\n* Calculated or measured creatinine Clearance ≥ 30 mL\u002Fmin\n\nExclusion Criteria:\n\n* KPS \\\u003C60\n* Second malignancy with a high metastatic potential within 3 years\n* Active CNS involvement. Treated CNS disease is allowed\n* Active HBV or HCV infection.\n* Active uncontrolled infections\n* Known HIV positive status\n* Allogeneic transplant within 100 days of enrollment\n* Active acute or chronic graft versus host disease\n* History of acute or chronic pancreatitis\n* History of myositis","ALL","8 Years",{"count":58,"type":59},29,"ESTIMATED","INTERVENTIONAL",[62],"PHASE1","Axatilimab + CAR-T in High-Risk Lymphoma",[65,66,67,68,69,70],"Diffuse Large B Cell Lymphoma (DLBCL)","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","High-grade B-cell Lymphoma (HGBCL)","High-Grade B-Cell Lymphoma, Nos","PMBCL","Follicular Grade 3 Lymphoma","NOT_YET_RECRUITING","2026-06-05",{"date":74,"type":75},"2026-06-10","ACTUAL",{"date":77,"type":59},"2026-10-31",{"date":79,"type":59},"2029-12-31",{"name":5,"class":6},1]